75 related articles for article (PubMed ID: 20921970)
1. A genetic marker at the OLIG3/TNFAIP3 locus associates with methotrexate continuation in early inflammatory polyarthritis: results from the Norfolk Arthritis Register.
Plant D; Farragher T; Flynn E; Martin P; Eyre S; Bunn D; Worthington J; Symmons D; Barton A; Thomson W
Pharmacogenomics J; 2012 Apr; 12(2):128-33. PubMed ID: 20921970
[TBL] [Abstract][Full Text] [Related]
2. Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis.
Kooloos WM; Wessels JA; van der Straaten T; Allaart CF; Huizinga TW; Guchelaar HJ
Pharmacogenomics; 2010 Feb; 11(2):163-75. PubMed ID: 20136356
[TBL] [Abstract][Full Text] [Related]
3. Studying associations between variants in TRAF1-C5 and TNFAIP3-OLIG3 and the progression of joint destruction in rheumatoid arthritis in multiple cohorts.
Knevel R; de Rooy DP; Gregersen PK; Lindqvist E; Wilson AG; Gröndal G; Zhernakova A; van Nies JA; Toes RE; Tsonaka R; Houwing-Duistermaat JJ; Steinsson K; Huizinga TW; Saxne T; van der Helm-van Mil AH
Ann Rheum Dis; 2012 Oct; 71(10):1753-5. PubMed ID: 22586175
[No Abstract] [Full Text] [Related]
4. SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of methotrexate-related toxicity in Portuguese rheumatoid arthritis patients.
Lima A; Bernardes M; Azevedo R; Monteiro J; Sousa H; Medeiros R; Seabra V
Toxicol Sci; 2014 Nov; 142(1):196-209. PubMed ID: 25124723
[TBL] [Abstract][Full Text] [Related]
5. The role of rheumatoid arthritis genetic susceptibility markers in the prediction of erosive disease in patients with early inflammatory polyarthritis: results from the Norfolk Arthritis Register.
Plant D; Thomson W; Lunt M; Flynn E; Martin P; Eyre S; Farragher T; Bunn D; Worthington J; Symmons D; Barton A
Rheumatology (Oxford); 2011 Jan; 50(1):78-84. PubMed ID: 20219786
[TBL] [Abstract][Full Text] [Related]
6. PTPN22 1858C>T polymorphism is strongly associated with rheumatoid arthritis but not with a response to methotrexate therapy.
Majorczyk E; Pawlik A; Kuśnierczyk P
Int Immunopharmacol; 2010 Dec; 10(12):1626-9. PubMed ID: 20888443
[TBL] [Abstract][Full Text] [Related]
7. TGF beta1 polymorphisms are candidate predictors of the clinical response to rituximab in rheumatoid arthritis.
Daïen CI; Fabre S; Rittore C; Soler S; Daïen V; Tejedor G; Cadart D; Molinari N; Daurès JP; Jorgensen C; Touitou I
Joint Bone Spine; 2012 Oct; 79(5):471-5. PubMed ID: 22129793
[TBL] [Abstract][Full Text] [Related]
8. Exploratory analysis of four polymorphisms in human GGH and FPGS genes and their effect in methotrexate-treated rheumatoid arthritis patients.
van der Straaten RJ; Wessels JA; de Vries-Bouwstra JK; Goekoop-Ruiterman YP; Allaart CF; Bogaartz J; Tiller M; Huizinga TW; Guchelaar HJ
Pharmacogenomics; 2007 Feb; 8(2):141-50. PubMed ID: 17286537
[TBL] [Abstract][Full Text] [Related]
9. Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis.
Wessels JA; Kooloos WM; De Jonge R; De Vries-Bouwstra JK; Allaart CF; Linssen A; Collee G; De Sonnaville P; Lindemans J; Huizinga TW; Guchelaar HJ
Arthritis Rheum; 2006 Sep; 54(9):2830-9. PubMed ID: 16947783
[TBL] [Abstract][Full Text] [Related]
10. Longterm retention rate and risk factor for discontinuation due to insufficient efficacy and adverse events in Japanese patients with rheumatoid arthritis receiving etanercept therapy.
Matsubara H; Kojima T; Kaneko A; Hirano Y; Ishikawa H; Hattori Y; Miyake H; Oguchi T; Takagi H; Yabe Y; Kato T; Ito T; Fukaya N; Kanayama Y; Shioura T; Hayashi M; Fujibayashi T; Takahashi N; Funahashi K; Kato D; Hanabayashi M; Terabe K; Ishiguro N
J Rheumatol; 2014 Aug; 41(8):1583-9. PubMed ID: 25028370
[TBL] [Abstract][Full Text] [Related]
11. Effect of allograft inflammatory factor-1 gene polymorphisms on rheumatoid arthritis treatment with methotrexate.
Pawlik A; Herczynska MM; Dziedziejko V; Malinowski D; Kurzawski M; Drozdzik M; Gawronska-Szklarz B
Postepy Hig Med Dosw (Online); 2013 Jul; 67():637-42. PubMed ID: 24018427
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for oral methotrexate failure in patients with inflammatory polyarthritis: results from a UK prospective cohort study.
Bluett J; Sergeant JC; MacGregor AJ; Chipping JR; Marshall T; Symmons DPM; Verstappen SMM
Arthritis Res Ther; 2018 Mar; 20(1):50. PubMed ID: 29554956
[TBL] [Abstract][Full Text] [Related]
13. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors.
Kapetanovic MC; Roseman C; Jönsson G; Truedsson L; Saxne T; Geborek P
Arthritis Rheum; 2011 Dec; 63(12):3723-32. PubMed ID: 21834061
[TBL] [Abstract][Full Text] [Related]
14. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis.
Dervieux T; Furst D; Lein DO; Capps R; Smith K; Walsh M; Kremer J
Arthritis Rheum; 2004 Sep; 50(9):2766-74. PubMed ID: 15457444
[TBL] [Abstract][Full Text] [Related]
15. Genome-wide analysis of methotrexate pharmacogenomics in rheumatoid arthritis shows multiple novel risk variants and leads for TYMS regulation.
Senapati S; Singh S; Das M; Kumar A; Gupta R; Kumar U; Jain S; Juyal RC; Thelma BK
Pharmacogenet Genomics; 2014 Apr; 24(4):211-9. PubMed ID: 24583629
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Symmons DP; Watson KD; Silman AJ;
Arthritis Rheum; 2006 Jun; 54(6):1786-94. PubMed ID: 16736520
[TBL] [Abstract][Full Text] [Related]
17. 2756GG genotype of methionine synthase reductase gene is more prevalent in rheumatoid arthritis patients treated with methotrexate and is associated with methotrexate-induced nodulosis.
Berkun Y; Abou Atta I; Rubinow A; Orbach H; Levartovsky D; Aamar S; Arbel O; Dresner-Pollak R; Friedman G; Ben-Yehuda A
J Rheumatol; 2007 Aug; 34(8):1664-9. PubMed ID: 17611986
[TBL] [Abstract][Full Text] [Related]
18. Brief report: candidate gene study in systemic sclerosis identifies a rare and functional variant of the TNFAIP3 locus as a risk factor for polyautoimmunity.
Koumakis E; Giraud M; Dieudé P; Cohignac V; Cuomo G; Airò P; Hachulla E; Matucci-Cerinic M; Diot E; Caramaschi P; Mouthon L; Riccieri V; Cracowski JL; Tiev KP; Francès C; Amoura Z; Sibilia J; Cosnes A; Carpentier P; Valentini G; Manetti M; Guiducci S; Meyer O; Kahan A; Boileau C; Chiocchia G; Allanore Y
Arthritis Rheum; 2012 Aug; 64(8):2746-52. PubMed ID: 22488580
[TBL] [Abstract][Full Text] [Related]
19. Analysis of TNFAIP3, a feedback inhibitor of nuclear factor-kappaB and the neighbor intergenic 6q23 region in rheumatoid arthritis susceptibility.
Dieguez-Gonzalez R; Calaza M; Perez-Pampin E; Balsa A; Blanco FJ; Cañete JD; Caliz R; Carreño L; de la Serna AR; Fernandez-Gutierrez B; Ortiz AM; Herrero-Beaumont G; Pablos JL; Narvaez J; Navarro F; Marenco JL; Gomez-Reino JJ; Gonzalez A
Arthritis Res Ther; 2009; 11(2):R42. PubMed ID: 19292917
[TBL] [Abstract][Full Text] [Related]
20. Genetic variation and alterations of genes involved in NFκB/TNFAIP3- and NLRP3-inflammasome signaling affect susceptibility and outcome of colorectal cancer.
Ungerbäck J; Belenki D; Jawad ul-Hassan A; Fredrikson M; Fransén K; Elander N; Verma D; Söderkvist P
Carcinogenesis; 2012 Nov; 33(11):2126-34. PubMed ID: 22843550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
